Orphan drug status accorded to antiobesity product

被引：0

|

作者：

不详

机构：

来源：

BIOTECHNOLOGY LAW REPORT | 1996年 / 15卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：589 / 589

页数：1

相关论文

共 50 条

[21] Preeclampsia - will orphan drug status facilitate innovative biological therapies?
Hahn, Sinuhe
[J]. FRONTIERS IN SURGERY, 2015, 2
[22] FDA grants orphan drug status to CEA-Cide
不详
[J]. BIOTECHNOLOGY LAW REPORT, 1999, 18 (01) : 43 - 43
[23] Drug for rare pediatric liver disease gains orphan status
不详
[J]. LABORATORY MEDICINE, 2002, 33 (03) : 176 - 176
[24] GENE-SPLICING PROTEIN TO HAVE ORPHAN DRUG STATUS
FOX, JL
[J]. SCIENCE, 1984, 223 (4639) : 914 - 914
[25] THE CURRENT STATUS OF ANTIOBESITY DRUGS
GALLOWAY, SML
FARQUHAR, DL
MUNRO, JF
[J]. POSTGRADUATE MEDICAL JOURNAL, 1984, 60 : 19 - 26
[26] FDA grants orphan drug status to 9-nitrocamptothecin
不详
[J]. BIOTECHNOLOGY LAW REPORT, 1996, 15 (06): : 916 - 916
[27] Trabedersen gains orphan drug status for treating pancreatic carcinoma
不详
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (12) : 1713 - 1713
[28] Lorcaserin: A novel antiobesity drug
Brashier, Dick B. S.
Sharma, A. K.
Dahiya, Navdeep
Singh, S. K.
Khadka, Anjan
[J]. JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2014, 5 (02) : 175 - 178
[29] Semaglutide as a promising antiobesity drug
Christou, Georgios A.
Katsiki, Niki
Blundell, John
Fruhbeck, Gema
Kiortsis, Dimitrios N.
[J]. OBESITY REVIEWS, 2019, 20 (06) : 805 - 815
[30] IS IT WORTH HAVING ORPHAN DRUG STATUS IN GERMANY POST-AMNOG?
Radicek, S.
Obradovic, M.
Rauland, M.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A391 - A391

← 1 2 3 4 5 →